IL98979A - Pharmaceutical preparations containing benzothiazol derivatives and their use in lowering the urinary level in the blood - Google Patents

Pharmaceutical preparations containing benzothiazol derivatives and their use in lowering the urinary level in the blood

Info

Publication number: IL98979A
Authority: IL; Israel
Prior art keywords: uric acid; acid levels; formula; hydroxy; compound
Prior art date: 1990-08-02

Application number

IL9897991A

Other languages

English (en)

Hebrew (he)

Other versions

IL98979A0 (en

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-08-02

Filing date

1991-07-27

Publication date

1996-11-14

1991-07-27 Application filed by Pfizer filed Critical Pfizer

1992-07-15 Publication of IL98979A0 publication Critical patent/IL98979A0/xx

1996-11-14 Publication of IL98979A publication Critical patent/IL98979A/en

Links

LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 22
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 22
229940116269 uric acid Drugs 0.000 title claims abstract description 22
239000008280 blood Substances 0.000 title claims abstract description 15
210000004369 blood Anatomy 0.000 title claims abstract description 15
239000008194 pharmaceutical composition Substances 0.000 title description 4
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 22
241000124008 Mammalia Species 0.000 claims abstract description 15
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 12
150000003839 salts Chemical class 0.000 claims abstract description 11
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 7
239000001257 hydrogen Substances 0.000 claims abstract description 7
125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 7
239000000651 prodrug Chemical group 0.000 claims abstract description 7
229940002612 prodrug Drugs 0.000 claims abstract description 7
125000001309 chloro group Chemical group Cl* 0.000 claims abstract description 3
125000001153 fluoro group Chemical group F* 0.000 claims abstract description 3
239000003937 drug carrier Substances 0.000 claims description 4
239000000203 mixture Substances 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
239000003814 drug Substances 0.000 claims 4
125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 claims 1
201000005569 Gout Diseases 0.000 abstract description 8
206010018634 Gouty Arthritis Diseases 0.000 abstract description 5
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract description 3
235000011054 acetic acid Nutrition 0.000 abstract 1
150000001242 acetic acid derivatives Chemical class 0.000 abstract 1
150000001243 acetic acids Chemical class 0.000 abstract 1
-1 BENZOTHIAZOLYL Chemical class 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
ONMJGGGSMBPLBH-UHFFFAOYSA-N 2-[4-(1,3-benzothiazol-2-yl)phthalazin-1-yl]-2-oxoacetic acid Chemical class S1C(=NC2=C1C=CC=C2)C1=NN=C(C2=CC=CC=C12)C(C(=O)O)=O ONMJGGGSMBPLBH-UHFFFAOYSA-N 0.000 description 5
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
239000002585 base Substances 0.000 description 5
239000003085 diluting agent Substances 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 3
239000012445 acidic reagent Substances 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
108010092464 Urate Oxidase Proteins 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000000945 filler Substances 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
NDQQRRVKUBPTHQ-QBIQUQHTSA-N (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO NDQQRRVKUBPTHQ-QBIQUQHTSA-N 0.000 description 1
GMTDTKUPJZRPBE-UHFFFAOYSA-N 2-[3-(4-bromo-2-fluorophenyl)-4-oxophthalazin-1-yl]acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1C1=CC=C(Br)C=C1F GMTDTKUPJZRPBE-UHFFFAOYSA-N 0.000 description 1
102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
102000016938 Catalase Human genes 0.000 description 1
108010053835 Catalase Proteins 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
208000031845 Pernicious anaemia Diseases 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000004040 coloring Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
208000014951 hematologic disease Diseases 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
238000000034 method Methods 0.000 description 1
208000025113 myeloid leukemia Diseases 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Investigating Or Analysing Biological Materials (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

IL9897991A 1990-08-02 1991-07-27 Pharmaceutical preparations containing benzothiazol derivatives and their use in lowering the urinary level in the blood IL98979A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/562,096 US5064830A (en)	1990-08-02	1990-08-02	Lowering of blood uric acid levels

Publications (2)

Publication Number	Publication Date
IL98979A0 IL98979A0 (en)	1992-07-15
IL98979A true IL98979A (en)	1996-11-14

Family

ID=24244779

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9897991A IL98979A (en)	1990-08-02	1991-07-27	Pharmaceutical preparations containing benzothiazol derivatives and their use in lowering the urinary level in the blood

Country Status (16)

Country	Link
US (1)	US5064830A (da)
EP (1)	EP0469837B1 (da)
JP (1)	JPH04234321A (da)
KR (1)	KR940002665B1 (da)
AT (1)	ATE113840T1 (da)
AU (1)	AU622590B2 (da)
CA (1)	CA2048235C (da)
DE (1)	DE69105069T2 (da)
DK (1)	DK0469837T3 (da)
HU (1)	HUT61665A (da)
IE (1)	IE64046B1 (da)
IL (1)	IL98979A (da)
MX (1)	MX9100450A (da)
NZ (1)	NZ239215A (da)
PT (1)	PT98509B (da)
ZA (1)	ZA916060B (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5391551A (en) *	1993-05-10	1995-02-21	Pfizer Inc.	Method of lowering blood lipid levels
IL120264A0 (en) *	1996-02-29	1997-06-10	Pfizer	Method of reducing tissue damage associated with non-cardiac ischemia
IL124236A (en) *	1997-05-05	2003-01-12	Pfizer	Pharmaceutical composition for treating or reversing diabetic cardiomyopathy comprising aldose reductase inhibitor
WO2011046800A1 (en) *	2009-10-13	2011-04-21	Wellstat Therapeutics Corporation	3-substituted compounds for reducing uric acid
WO2017176777A1 (en) *	2016-04-04	2017-10-12	Aviragen Therapeutics, Inc.	Bta-c585 for the treatment and/or prevention of conditions related to or associated with hyperuricemia or hyperuricosuria and other conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL80475A (en) *	1985-11-07	1993-01-31	Pfizer	Heterocyclic-substituted 4-oxo (or thio)-3h- phthalazinyl-acetic acid derivatives and pharmaceutical compositions containing them
US4939140A (en) *	1985-11-07	1990-07-03	Pfizer Inc.	Heterocyclic oxophthalazinyl acetic acids
GB8704569D0 (en) *	1987-02-26	1987-04-01	Ici America Inc	Therapeutic agent
JPH0676391B2 (ja) *	1987-06-09	1994-09-28	フアイザー・インコーポレイテツド	ベンゾチアゾール等の複素環側鎖を有するオキソフタラジニル酢酸類の製造方法
EP0322153A3 (en) *	1987-12-21	1990-08-16	Pfizer Inc.	Heterocyclic oxophtalazinyl acetic acids

1990
- 1990-08-02 US US07/562,096 patent/US5064830A/en not_active Expired - Lifetime
1991
- 1991-07-27 IL IL9897991A patent/IL98979A/en not_active IP Right Cessation
- 1991-07-29 DE DE69105069T patent/DE69105069T2/de not_active Expired - Fee Related
- 1991-07-29 DK DK91306944.9T patent/DK0469837T3/da active
- 1991-07-29 EP EP91306944A patent/EP0469837B1/en not_active Expired - Lifetime
- 1991-07-29 AT AT91306944T patent/ATE113840T1/de not_active IP Right Cessation
- 1991-07-31 CA CA002048235A patent/CA2048235C/en not_active Expired - Fee Related
- 1991-07-31 MX MX9100450A patent/MX9100450A/es unknown
- 1991-07-31 PT PT98509A patent/PT98509B/pt active IP Right Grant
- 1991-08-01 HU HU912567A patent/HUT61665A/hu unknown
- 1991-08-01 KR KR1019910013330A patent/KR940002665B1/ko not_active Expired - Fee Related
- 1991-08-01 JP JP3193231A patent/JPH04234321A/ja active Pending
- 1991-08-01 ZA ZA916060A patent/ZA916060B/xx unknown
- 1991-08-01 IE IE272191A patent/IE64046B1/en not_active IP Right Cessation
- 1991-08-01 AU AU81560/91A patent/AU622590B2/en not_active Ceased
- 1991-08-01 NZ NZ239215A patent/NZ239215A/en unknown

Also Published As

Publication number	Publication date
AU622590B2 (en)	1992-04-09
EP0469837A2 (en)	1992-02-05
PT98509B (pt)	1999-01-29
KR940002665B1 (ko)	1994-03-28
US5064830A (en)	1991-11-12
AU8156091A (en)	1992-02-06
IL98979A0 (en)	1992-07-15
DE69105069T2 (de)	1995-03-09
EP0469837B1 (en)	1994-11-09
NZ239215A (en)	1997-07-27
IE912721A1 (en)	1992-02-12
DE69105069D1 (de)	1994-12-15
CA2048235C (en)	1995-05-30
KR920003970A (ko)	1992-03-27
IE64046B1 (en)	1995-06-28
ZA916060B (en)	1993-03-31
MX9100450A (es)	1992-04-01
HUT61665A (en)	1993-03-01
ATE113840T1 (de)	1994-11-15
JPH04234321A (ja)	1992-08-24
EP0469837A3 (en)	1992-04-08
DK0469837T3 (da)	1994-12-27
HU912567D0 (en)	1992-01-28
PT98509A (pt)	1992-06-30

Legal Events

Date	Code	Title
1997-04-15	FF	Patent granted
1997-07-13	KB	Patent renewed
1997-11-20	KB	Patent renewed
2001-06-14	RH	Patent void

Publication	Publication Date	Title
AU724327B2 (en)	2000-09-14	Method of reducing tissue damage associated with non-cardiac ischemia
US5728704A (en)	1998-03-17	Substituted pyridmidines for control of diabetic complications
IE880142L (en)	1988-08-24	Compositions comprising ac enzyme inhibitor stabilized¹against degradation
JPH02235821A (ja)	1990-09-18	血清コレステロール低下剤
US5990111A (en)	1999-11-23	Aldose reductase inhibition in preventing or reversing diabetic cardiomyopathy
CA2048235C (en)	1995-05-30	Lowering of blood uric acid levels
HU199684B (en)	1990-03-28	Process for producing pharmaceutical compositions containing 2-pyrimidinyl-1-piperazin derivatives against alcoholism
JP3153070B2 (ja)	2001-04-03	血中脂質レベルを低下させる方法
EP0132994B1 (en)	1988-06-01	Compounds for lowering lipid levels
EP0319288B1 (en)	1992-10-14	dl-5-[(2-benzyl-3,4-dihydro-2H-benzopyran-6-yl)methyl]thiazolidine-2,4-dione as an anti-atherosclerosis agent
Sharkawi	1979	Inhibition of alcohol dehydrogenase by dimethyl formamide and dimethyl sulfoxide
CA2024181C (en)	1994-11-08	Method of treating chemical dependencies using sertraline
IL89401A (en)	1994-05-30	Medicaments containing 1,4-dihydropyridine derivatives for the treatment of alcohol addiction and their preparation
WO1995003800A1 (en)	1995-02-09	Non-racemic compositions of spirofluorenehydantoins
JPS62158216A (ja)	1987-07-14	薬物の製造方法
JP3034169B2 (ja)	2000-04-17	活性酸素種の消去剤
US3941888A (en)	1976-03-02	Substituted or unsubstituted p-alkanoyl toluenes as hypolipidemics
CA2032487A1 (en)	1990-12-17	Noortopic agent
WO1996007415B1 (en)	1996-04-11	Myocardial protection using benzothiazepinones
MXPA96005153A (en)	1998-10-23	Pharmaceutical agents for the treatment of chronic and agu inflammatory diseases